Rilevera enables security teams to write, test, document, and deploy cyber threat detection rules from a centralized, easy-to-use platform

FULTON, Md., Nov. 4, 2025 — DataTribe, a global cyber foundry that invests in and co-builds next-generation cybersecurity and artificial intelligence (AI) companies, today announced a seed investment of $3 million in Rilevera, a New Jersey-based startup that empowers detection engineering teams to easily manage and maintain effective cyber threat detection by automating detection management workflows.

Modern cyber threats are evolving faster than traditional detection methods can identify.

Rilevera’s platform manages, deploys, and monitors detection rules to close coverage gaps and maintain operations without requiring any manual code writing. With a single click, security teams can download system health reports and automated coverage insights for a comprehensive overview of a security system’s performance and vulnerabilities.

Rilevera is already serving a growing number of customers in the fintech, financial services, and technology sectors.

“Traditional detection-as-code approaches centralize detection rules into a code repository with the intention of helping detection engineers manage the rules. But ultimately, it only burdens already exhausted security teams who are not developers and are ill-equipped to handle code,” said Andy Hunn, Partner, DataTribe. “Rilevera’s pioneering platform is formalizing the management and maintenance of the detection engineering process, giving security teams a complete diagnostic of their security operations.”

Rilevera was developed with input from leaders of more than 30 different organizations that voiced frustrations about insufficient detection rules that constantly break and omit critical threat coverage, burdening security teams with tedious and time-consuming maintenance.

Rilevera’s detection engineering at scale is purpose-built for security teams who need to detect, respond, and adapt to advanced threats. It offers:

• Automated Detection Validation – Users know instantly whether a detection rule is actually working in production, and Rilevera automatically tests and re-tests detections using real data.
• Change Control for Security Detections – Customers can apply version control to every detection, giving security teams a complete audit trail of what changed, who changed it, and whether it made things better or worse.
• Detection Health Monitoring – Across all tools, Rilevera shows users which rules are firing, which are noisy, and which are silently broken.
• AI-Powered Detection Tuning – Rilevera’s intelligence engine learns from users’ environment to optimize rule logic, reduce false positives, and close coverage gaps.
• SIEM-Agnostic Normalization – Teams can create and manage detections centrally and then push them to any SIEM platform.
• Zero-Friction Detection Onboarding – With Rilevera, detection engineers can turn ideas into tested, validated, documented detections fast.

“As a security practitioner turned entrepreneur, I know the pain points security teams face every day in trying to keep pace with evolving, relentless security threats,” said Ethan Smart, Co-Founder and CEO, Rilevera. “Rilevera transforms detection engineering from a guessing game to a system of record that makes security teams’ lives easier – not harder. We look forward to working with DataTribe to expand Rilevera’s operations and upend the detection engineering sector.”

Rilevera will use the seed money to expand and accelerate product development, hire new talent, and scale customer acquisition efforts. The funding will also support go-to-market strategies and other key operational initiatives as the company matures.

Rilevera joins an esteemed group of DataTribe portfolio companies that include Dragos, Strider, and BlackCloak. Earlier this year, the foundry closed a $41 million fund – its third in a decade.

For more information about DataTribe, please visit https://datatribe.com/. For more information about Rilevera, please visit https://rilevera.com/.

About DataTribe
DataTribe is a startup foundry that invests in and co-builds world-class startups focused on generational leaps in cybersecurity and data science. Founded by leading investors, startup veterans, and alumni of the U.S. intelligence community, DataTribe commits capital, in-kind services, access to an unparalleled network, and decades of professional expertise to give their companies an unfair advantage. DataTribe is headquartered in the Washington-Baltimore metro area in Fulton, Maryland. For more information, visit https://datatribe.com.

About Rilevera
Rilevera empowers security teams to easily manage and maintain effective threat detection by automating detection management workflows. We streamline the creation, deployment, and maintenance of detection rules, giving teams the power of developer-grade workflows in a simple, intuitive platform. To learn more, please visit https://rilevera.com/.

Media Contact:
Matthew Bowen
[email protected]

SOURCE DataTribe

HALIFAX, NS, Nov. 4, 2025 – Cove Soda, a Canada-based functional carbonated soft drink (CSD) brand, today announced that the company has closed a $15 million USD Series A round led by Vanterra Ventures, a leading venture and growth equity fund known for backing high-growth consumer health companies. The round also includes investment from RiverPark Ventures, The Palm Tree Crew, Simple Food Ventures, Diplo, Miles Teller, The Chainsmokers, Michael Rubin, Dan Lourenco, Jack Eichel, Aaron Ekblad, Matt Chapman, and JD Martinez. This new funding will support the company’s continued rapid growth across North America, the introduction of new flavors, and the hiring of key talent.

Since launching its zero-sugar probiotic sodas in 2023, Cove has seen explosive growth across Canada and the U.S. where it can be found in over 7,000 retail doors including Costco, Target, Whole Foods Market, and Sprouts. Cove also recently announced a major distribution partnership with Keurig Dr. Pepper (KDP) Canada where KDP will use their expansive distribution network and strong retail relationships to accelerate Cove Soda’s market penetration even further.

“Cove represents the next wave of innovation in the $250 billion carbonated soft drink market,” said John MacLellan, Co-Founder & CEO at Cove. “Partnering with Vanterra Ventures marks an exciting step forward as we accelerate our momentum and bring our vision to life heading into 2026 and beyond.”

Cove was founded in Halifax, Nova Scotia, by brothers John and Ryan MacLellan who were seeking healthier everyday refreshments that reminded them of their childhood. Ryan, the Chief Innovation Officer with a background in physics, has meticulously crafted each flavor to most closely resemble the delicious, nostalgic flavors that consumers crave, while hitting on function. “Flavor is at the forefront of everything we do at Cove,” he said.

“At Vanterra, we seek out innovative companies disrupting massive markets within consumer health,” said Ellis Fried, Principal at Vanterra Ventures, who has joined Cove’s Board of Directors. “Cove is emblematic of that strategy as it brings the world’s first zero-sugar functional soda to market with delicious, nostalgic flavors, quickly winning over consumers across North America.”

Consumers can purchase Cove Soda on Amazon and at thousands of retailers across North America including Costco, Target, Whole Foods, and Sprouts. To stay up to date on the latest news and product launches, visit www.covedrinks.com and follow the brand on Instagram and TikTok.  

SOURCE Cove Drinks

NYC-based business emerges from stealth, building the data layer that will drive AI transformation 

NEW YORK, Nov. 4, 2025 — Parable, the first intelligence layer for enterprise operations, has raised an $16.5 million Seed round, led by HOF Capital, with participation from Story Ventures and InMotion Ventures, alongside existing investors Lasagna, Panache, Supercharge, and Tripe Impact Capital. The round also included a number of renowned angel investors, including the founders of companies such as Hubspot, Vimeo, Deel, Ramp, and Superhuman. 

Parable, started by four second-time founders, is leading a category-defining moment. It provides large enterprises with deep organizational observability of time spent across all processes, strategies, and projects: passively understanding how teams use their time in order to drive organizational-wide AI transformation. 

AI is transforming enterprise operations, but these new tools are only as powerful as the data that guides them, and right now, there’s no data layer for measuring, managing, and maximizing operational efficiency, or AI’s impact at scale.

Parable is intelligence for enterprise operations. With Parable leaders can answer their two most important questions: What do we do about AI and how do we know it’s working? Parable contextualizes and categorizes activity data from across the workplace software stack. This data layer visualizes and quantifies how time is spent across operations and can simulate how to spend it more efficiently with AI. As agentic solutions are implemented, Parable is the canonical measurement system for every other AI tool in the company stack. They accomplish this through a continuous improvement process and AI product:

• Establish Baseline: Parable’s AI quantifies and visualizes how an enterprise organization spends its time. This triages the most impactful use cases for AI.
• Take Action: With expensive waste identified – take action in the form of AI automations and change management to effect the baseline.
• Measure Impact: Parable is the only product on the market that can measure AI automations and ensure that efficiency gains are realized as genuine operating leverage.

Within a private instance, Parable ingests millions of activity data points from across the workplace stack, creating an ontology and chronology of organizational work. This queryable ontology powers a dashboard of data visualizations and reporting that decode how collective time is spent, and where it’s being lost.

Parable is already having real world impact. “This data is a gift. It’s one of the most insightful data packages I’ve received” says Mary Powell, the CEO at Sunrun. The platform identified $80 million in cost savings and operational leverage through AI transformation and organizational redesign. According to the company, those changes helped the client’s market cap grow 2.5×.

Adam Schwartz, CEO says: “We’ve built an intelligence layer that is changing the way enterprises operate. Businesses know more about their customers than they do about how they operate internally, and by providing holistic observability into time-spend and by measuring the impact of their AI implementations we can close this data gap for the first time.”

Hansae Catlett from HOF Capital says: “Every enterprise is racing to implement AI, yet most lack the baseline data to do it effectively. By unlocking a true understanding of how work happens, Parable enables organizations to embrace AI not as a bolt-on tool, but as a structural transformation that drives real efficiency gains. We see an enormous market opportunity here, and the Parable team is uniquely positioned to capture it.”

Headshots, logo, and visuals available upon request.

For more information email: [email protected]

SOURCE Parable

Company to lean into massive structural opportunity on the back of the US-China deal

SAN FRANCISCO, Nov. 4, 2025 — Ceres AI, the data and artificial intelligence company transforming how the world understands agricultural and environmental risk, today announced new funding led by Remus Capital.

This investment strengthens Ceres AI’s ability to deliver industry-leading products for its blue-chip customer base that includes some of the world’s largest agribusiness and financial services companies. Ceres also plans to expand its Artificial Intelligence for Agricultural Intelligence (‘AI for AI’) platform, underpinned by data across 40 crop types, for its enterprise customers. The company has analyzed over 17 billion plant-level measurements across 32 million acres globally.

“Agriculture is entering its AI era,” said Ramsey Masri, CEO of Ceres AI. “Our goal is to help create the agricultural intelligence layer to enable faster and smarter decisions. We’re the only company that can help craft the future with our large financial services and agribusiness customers who trust us with this partnership. I’m excited to scale the most robust dataset in agriculture and deploy AI systems that deliver agricultural intelligence into the insurance, lending, and operational workflows across the value chain.”

As part of this transaction, John Tincoff, Partner at Remus Capital, will join the board and Remus will also appoint an AI agent, Arista, to the board.

“We’re proud to continue our partnership with Ceres. In every industry, we see compelling opportunities to move toward the next industrial operating systems with many powered by machines that SAY, SEE, and DO to support human teams. Ceres has an unfair advantage to develop ‘AI for AI,’ said Tincoff.” 

“We’re also appointing the world’s first AI board member in one of our board seats at Ceres, which is aligned with our ethos to elevate what we can do as investors who work to help founders build great companies. We are looking forward to collaborating with Arista.”

“Appointing an AI board member is more than a symbolic gesture – it’s a functional and strategic step,” said Masri. “Arista will contribute data-backed input to elevate our leadership team’s decision-making and help us stay accountable.”

About Ceres AI

Ceres AI is a data and artificial-intelligence company delivering high-resolution insights that transform agricultural and financial decision-making. Its proprietary platform combines advanced imagery, AI analytics, and field-scale data to help agribusinesses, insurers, and lenders manage risk and improve outcomes.

Ceres AI is headquartered in San Francisco, California, with operations across North America, Europe, Latin America, and Australia. Learn more at www.ceres.ai.

About Remus Capital

Remus Capital is the leading partner to founders building Vertical AI businesses. Founded out of MIT, we have 15 years of experience commercializing machines that SAY-SEE-DO (Voice, Vision, Robotics) in each industry that powers our global economy.

Media Contact: Anubhav Sharma, [email protected]

SOURCE CeresAI

NEW CASTLE, Del., Nov. 4, 2025 — IgniteData, a leader in intelligent clinical trial data automation, today announced the final close of its oversubscribed Series A funding round. This close brings the total capital raised in the round to $11M, fueling IgniteData’s expansion of its global research site network, advancement of its flagship product, Archer, and acceleration of innovation in generative AI–powered data automation.

IgniteData’s Archer platform enables the seamless transfer of clinical trial data from source systems, such as electronic health records (EHRs), to electronic data capture (EDC) systems and data warehouses, thereby reducing site burden and accelerating trial timelines. With this investment, IgniteData will continue to scale globally and build on its work with large language models and intelligent data mapping to unlock previously inaccessible clinical data, improve trial speed and data quality, and transform sponsor–site collaboration.

The round was led by FCA Venture Partners, with the Labcorp Venture Fund and Epsilon anchoring the final close as the primary investors. Strong participation also came from existing investors, including SpringTide and Oncology Ventures, alongside a group of distinguished new investors bringing unparalleled industry experience.

IgniteData is proud to welcome Thomas Tarnowski and Marc Vangerven, both seasoned investors with deep expertise in scaling high-growth healthcare and technology companies, as well as Andy Cooper, CEO of CluePoints and a recognized leader in biopharma technology. Their decision to participate personally in this round reflects a powerful vote of confidence in IgniteData’s mission and momentum.

“This round is about scale,” said Zach Taft, CEO of IgniteData. “The demand for smarter, faster clinical trials is exploding. With Labcorp and Epsilon joining as primary investors in our Series A, and with the addition of Thomas, Marc, and Andy to our team, we gain not just capital but also invaluable expertise and endorsement from leaders who have shaped this industry. Their confidence underscores the transformative potential of our platform — particularly as we continue to harness generative AI and intelligent data mapping to fundamentally change how clinical data flows between sites and sponsors.”

Quotes from New Investors

“At Labcorp, we see tremendous value in innovations that reduce site burden and enable more efficient, higher-quality clinical trials,” said Megann Vaughn Watters, Vice President of New Ventures and Strategic Alliances for Labcorp. “We’re thrilled to support IgniteData on their journey to transform the way hospitals, research sites and sponsors transfer patient data for clinical research and trials.”

“Epsilon is committed to advancing healthcare through cutting-edge technology and data-driven solutions. IgniteData’s approach to intelligent data automation is transformative for clinical trials, and we are excited to support their continued growth and global expansion,” said Gregory Epstein, Managing Partner.

Backing From Existing Investors

Returning investors reaffirmed their confidence by increasing their positions.

“We backed IgniteData early because we believed in their vision to revolutionize clinical trials through intelligent automation. Today, we’re doubling down because they’ve exceeded expectations,” said Ryan Morley, Partner at SpringTide.

About IgniteData

IgniteData is on a mission to revolutionize clinical trials through intelligent automation. By enabling real-time, secure transfer of clinical data between healthcare providers and life science companies, IgniteData accelerates research while reducing burden on clinical sites. With deployments across premier research centers, partnerships with top pharmaceutical sponsors, and cutting-edge use of generative AI and intelligent data mapping, IgniteData is redefining what’s possible in clinical trial operations.

SOURCE IgniteData

With support from Album VC and SignalFire, Ruli’s AI-native platform introduces continuous legal intelligence—an always-on system built to transform how corporate legal teams operate.

SAN FRANCISCO, Nov. 4, 2025 — Ruli.ai, a next-generation legal intelligence platform built by experienced lawyers and expert technologists from Google and Meta, today announced $6 million in seed funding, bringing its total funding to $8 million in just over a year. The round was led by Album VC, with participation from SignalFire, PJC, Foothill Ventures, Mana, and Genius Ventures.

“SignalFire exists to back category leaders before the category exists. Our data platform flagged an inflection in how AI is transforming legal operations by embedding intelligence directly into the enterprise stack,” says Wayne Hu, Partner, SignalFire. “Ruli executes this vision with a rare combination of technical depth and domain credibility. Their continuous legal intelligence model represents exactly the kind of defensible, data-centric company we built our $1B+ platform to find and scale.”

Pioneering a new era of continuous legal intelligence, Ruli has built an AI infrastructure that understands a company’s unique business, operational context, and evolving regulatory landscape. Unlike one-size-fits-all contract tools or AI chatbots, Ruli’s system continuously learns from both internal company data and global legal updates to deliver proactive, personalized guidance in real time, all while ensuring customer data is secure and confidential.

With this funding the company also announces the addition of Michele Lee, former General Counsel of Pinterest and current GC in Residence at Wilson Sonsini, to its Board of Advisors, bringing extensive experience bridging technology, law, and corporate governance, reinforcing Ruli’s mission to modernize in-house legal operations with AI-native intelligence.

“Our vision is to make legal expertise as dynamic and responsive as the businesses it serves,” said Bryan Lee, CEO and Co-founder of Ruli.ai. “We have built a system that goes beyond automation and becomes a digital legal brain of your company. This isn’t about replacing lawyers; it’s about creating resources and providing intelligence that works continuously, contextually, and collaboratively for better results.”

Designed for in-house legal teams, Ruli’s platform enhances the ability of an in-house lawyer or legal ops manager to work better and faster, assisting the legal team with helping to address the core issues that are important to the business.  Ruli reduces dependency on external counsel and costly manual processes by integrating directly into existing workflows, such as Microsoft Word and internal document systems. The technology allows corporate legal departments to stay ahead of regulatory changes, streamline contract review and management, and scale compliance operations without additional headcount or outside counsel expense.

The funding will accelerate team expansion, product development, and market adoption of Ruli’s legal intelligence suite, including its real-time AI assistant, contract redlining tool and upcoming intelligent archive.

Ruli’s seasoned leadership team comes from Google, Meta and prestigious law firms and in-house legal teams that draw from deep experience in both legal practice and advanced technology, blending AI innovation with firsthand knowledge of the inefficiencies facing modern legal departments.

Visit www.ruli.ai/demo to see how Ruli is redefining the legal workspace.

About Ruli.ai

Ruli.ai is an AI-native legal intelligence platform that empowers in-house legal teams to operate with always-on, context-aware insight. Built by experienced lawyers and expert technologists from Google and Meta, Ruli transforms static legal processes into dynamic systems that continuously learn from a company’s data, operations, and regulatory environment. The result: faster, smarter, and more strategic legal operations for the modern enterprise. Learn more at www.ruli.ai

Media Contact:

Ronjini Joshua
Silver Telegram for Ruli.ai
[email protected]
(949) 295-9779
www.ruli.ai

SOURCE Ruli.ai

WASHINGTON, Nov. 4, 2025 — Parent Project Muscular Dystrophy (PPMD), the largest U.S. non-profit leading Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and MyoGene Bio (MyoGene) are excited to announce that PPMD has provided $400,000 in funding to MyoGene through PPMD Venture Pathways, the organization’s venture-philanthropy initiative that provides industry funding to accelerate therapeutic development for Duchenne and Becker. This funding commitment aims to advance the development of MyoGene’s gene editing strategy and potentially leverage additional funding from other awards to support studies that pave the way to the clinic.

Duchenne , the most common genetic disorder diagnosed in childhood that affects approximately one in 5,000 live male births, is caused by a change in the DMD gene that codes for the dystrophin protein. Gene editing is a strategy to make permanent alterations to an individual’s DNA to restore function of the gene.

MyoGene’s strategy, known as MyoDys^45-55, utilizes gene editing technology to edit an individual’s DMD gene. They target a large deletion of exons 45-55, encompassing a hotspot of disease-causing variants and creating an in-frame deletion that restores dystrophin production. MyoGene’s approach mimics a deletion found in mild Becker muscular dystrophy, associated with production of a highly functional dystrophin protein. This type of deletion and re-framing of the DMD gene would be amenable for approximately 50% of individuals with Duchenne. Unlike gene therapies that deliver a dystrophin transgene where durability is unknown, editing the DNA represents a permanent alteration.

“PPMD has been committed through our Gene Therapy Initiative to continue to push the field of gene therapy forward. Through PPMD Venture Pathways, we can help usher in yet another approach for treating patients with Duchenne,” explains Eric Camino, PhD, PPMD’s Vice President of Research and Clinical Innovation. “Gene editing represents a strategy to make life-long corrections to variants in patients’ DNA. Supporting the development of this approach will also further our understanding of novel precision medicine strategies to treat Duchenne.”

PPMD’s support will enable MyoGene to conduct key studies to advance towards the clinic. MyoGene will generate data comparing the functionality of their corrected 45-55 deletion dystrophin protein to other dystrophins and advance work on characterization of safety of this approach.

PPMD’s investment and additional funds, including from Duchenne UK and How Women Invest, represent $1.42 million in total support for MyoGene. This funding commitment may be leveraged for additional non-dilutive grant funding, building on MyoGene’s previous success obtaining grants.

“Support from patient advocacy organizations like PPMD is vital to our work,” shares Courtney Young, PhD, CEO and Co-founder of MyoGene Bio. “This support not only provides critical funding to advance our research, but also sends a powerful signal to public and private funders about the importance of continued innovation in therapeutic development for Duchenne. With PPMD’s investment, we will be able to leverage patient-advocacy funding into larger awards, making this funding reach further as we advance development of our novel gene editing therapy for Duchenne.”

PPMD’s investment in MyoGene builds on the organization’s 30-year legacy of funding more than $55 million in Duchenne and Becker research to enhance our knowledge of dystrophinopathies. In addition to substantial preclinical and academic research funding, PPMD’s Venture Pathways program provides funding to biopharmaceutical companies, which allows companies to complete critical studies needed to advance investigational products to the clinic. These funding commitments also create the opportunity for PPMD to have a financial return that can be reinvested into its research strategy and support additional work in the future. All of PPMD’s research-funding commitments undergo rigorous scientific evaluation and are selected on the basis of potential benefit to the Duchenne and Becker community. Learn more about PPMD’s Venture Pathways program.

About MyoGene Bio

MyoGene Bio is a privately held biotech company based in San Diego, CA dedicated to developing next-generation genetic therapies for Duchenne and other muscle diseases. Our lead program is a gene editing therapy for Duchenne muscular dystrophy. Learn more here: https://www.myogenebio.com/ or follow our LinkedIn page: https://www.linkedin.com/company/myogene-bio/.

About Parent Project Muscular Dystrophy

Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne.

We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won eight FDA approvals.

Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube.

SOURCE Parent Project Muscular Dystrophy (PPMD)

Recognition from the region’s leading venture summit underscores investor confidence in Worlds’ rapid growth and its role in redefining how enterprises see, sense, and automate the physical world.

DALLAS, Nov. 4, 2025 — Worlds has been named “Startup of the Year” by Venture Dallas at the 2025 Venture Dallas Summit, held at the George W. Bush Institute and Presidential Library. The company was selected from more than 130 startups—the largest pool of candidates to date—and down-selected to one of six finalists in the Series A category before being named Startup of the Year. Worlds’ recognition marks a pivotal moment as Physical AI moves from early vision to enterprise reality, transforming how organizations integrate AI into physical operations.

The Worlds platform is a foundational AI technology that is transforming how enterprises operate in the physical world. While other branches of Physical AI focus on autonomous vehicles and robotics, Worlds is enabling the creation of intelligent environments by connecting to existing cameras and sensors and converting real-world processes into live spatial data. Within these environments, organizations can deploy AI agents and agentic workflows that secure, automate, and accelerate their most critical operations, bringing Physical AI to life inside the enterprise.

“This award recognizes more than our company—it validates a fundamental shift in how intelligence and automation are being woven into the fabric of the physical world,” said Dave Copps, CEO and Co-founder of Worlds. “Physical AI is no longer a future technology—it’s happening today. It’s giving enterprises the power to see their operations at scale, and unlock transformative gains in productivity, efficiency, and safety. We’re honored to represent this movement here in Dallas and could not have done it without our amazing investors led by Align Capital, Moneta Ventures, GPG Ventures and Strategic investors Chevron Technology Ventures and PIVA.”

“2025 is the year physical AI goes mainstream,” said Chris Rohde, Co-founder and President of Worlds. “This isn’t incremental improvement – this is structural change on a massive scale. Our platform currently operates across facilities spanning up to 4 square miles, orchestrating cameras, vehicle transponders, personnel badges, and dozens of sensor types in real time—true sensor fusion at enterprise scale.”

“Worlds represents everything Venture Dallas stands for—radical innovation rooted in North Texas, solving real-world challenges with transformative technology,” said Bryan Chambers, Co-founder of Venture Dallas. “This recognition isn’t just about one company’s success; it reflects the strength and momentum of our region as a hub for world-changing AI innovation.”

David Evans, Managing Partner of Sentiero Ventures and member of the Venture Dallas Steering Committee, added: “When you see a team that has cracked both the technology and the market timing, you recognize something special. Worlds has done both. Their ability to deploy AI at true enterprise scale, across existing infrastructure, positions them at the epicenter of a multi-trillion-dollar transformation. This award is a well-deserved recognition of their exceptional execution.”

The Venture Dallas “Startup of the Year” award celebrates innovation, growth potential, and the capacity to meaningfully impact industries and communities. Worlds’ selection underscores North Texas emergence as a hub for breakthrough technology and the region’s role in shaping the future of AI.

About Worlds

Worlds has created an end-to-end open AI platform for the physical world. By connecting to an organization’s existing cameras and sensors, Worlds converts real-time sensor data into live spatial intelligence, enabling enterprises to deploy AI Agents and autonomous applications across their physical operations at unprecedented scale. From commercial distribution centers, manufacturing facilities, and logistics operations to mission-critical Federal facilities spanning square miles, Worlds AI empowers the world’s largest organizations to measure, automate, and optimize their physical world. Learn more at www.worlds.io.

About Venture Dallas

Venture Dallas is a 501(c)(6) non-profit organization dedicated to growing the innovation ecosystem in North Texas by connecting early-stage investors, venture capitalists, and high-growth companies. Through its annual conference, networking events, and recognition programs, Venture Dallas helps facilitate collaboration and investment across key sectors including technology, healthcare, and defense. For more information, visit https://www.venturedallas.org/.

Media Contact:

Breana Long
Director of Marketing, Worlds
[email protected]
(817)357-2064
www.worlds.io

SOURCE Worlds

First and leading GenAI Adoption Management Platform continues accelerated growth, innovation for enabling high-impact enterprise GenAI adoption

LOS GATOS, Calif., Nov. 4, 2025 — GenAI Adoption Management Platform Portal26 today announced a $9 Million Series A round of funding led by Shasta Ventures. The round was also supported by leading AI and deep tech investor, Fusion Fund, as well as the venture arm of a Fortune 500 financial services institution. The company previously raised a seed round of $6 Million in 2022. Portal26 will use the proceeds to continue its accelerated growth and product innovations. 

“As enterprises across the world invest in Generative AI, they understand that a platform to manage and measure all aspects of AI adoption is essential to fully realize the potential of this transformative technology. We built Portal26 to provide the visibility, security, governance, and strategic analytics necessary for companies to manage their transition for the new normal of how work gets done in the enterprise,” said Arti Raman, CEO, Portal26. “We are excited to partner with Shasta to expand our ability to enable companies to successfully extract the full value of Generative AI.” 

“At Shasta Ventures, we look for visionary founders and companies who are solving important problems in transformative ways. We are excited to partner with Portal26 and to provide the resources and support needed to accelerate its growth.” said Jacob Mullins, Managing Director, Shasta Ventures.  “As the first and leading GenAI Adoption Management Platform, its innovative approach to finding GenAI in the enterprise, securing it, and enabling measurable ROI, is a great example of the kind of leadership and creativity we seek to back. We look forward to helping Portal26 continue to build something extraordinary and sustain its strong growth.”

“Fusion Fund is delighted to support Portal26 as it continues its impressive journey to becoming the trusted platform for GenAI governance, security, and strategy in the enterprise,” said Lu Zhang, Founder and Managing Partner, Fusion Fund. “This round comes at a time when Portal26 has a mature, enterprise-grade solution that monitors hundreds of thousands of enterprise GenAI users. With exceptionally high customer trust and excellent support from ecosystem partners, Portal26 is poised for strong growth.”

In addition to the funding announcement, Raman said the company continues to hit significant milestones, with major customer wins and prominent partnerships across the security, systems integrator, reseller, and hyperscaler ecosystems.

“Portal26 stands apart from our competitors in both the quality and quantity of customers we have,” said Raman. “A vast majority of these customers have made large multi-year commitments of up to 7 figures. This reflects their tremendous confidence in both our current platform as well as our ability to grow features at the fast pace of the broader AI market.”

Raman noted that in the two years since the Portal26 GenAI Adoption Management Platform was launched, it has grown to become the industry’s richest and most complete resource for governing the consumption of GenAI in the enterprise. Available in a variety of standalone as well as integration-based architectures, Portal26 encompasses real-time zero-day ShadowAI detection, GenAI security and policy enforcement, GenAI Forensic Audit, GenAI Risk Management, GenAI intent and use case analysis, GenAI cost and license analytics, GenAI Strategy, GenAI Policy Management, and GenAI Employee Education.

About Portal26

Portal26 is the GenAI Adoption Management Platform that helps enterprises embrace and accelerate the competitive promise of Generative AI. It provides the essential foundation for complete GenAI visibility to manage users, drive program ROI, establish governance, ensure security, and deliver targeted education. Regardless of your current stage of enterprise GenAI adoption, Portal26 rapidly enables your buildout of a trusted, responsible GenAI program that lifts organizational competitiveness and ignites unprecedented productivity and revenue gains.  Learn more at portal26.ai.

SOURCE Portal26, Inc.